Roivant Sciences (ROIV) Q3 Loss Of US$265.9 Million Tests Bullish Profitability Narrative

Simply Wall St.

02/08

Roivant Sciences (ROIV) just posted its Q3 2026 numbers with total revenue of about US$2.0 million and a basic EPS loss of US$0.38, alongside a net income loss, excluding extra items, of US$265.9 ...

网页链接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2609578298"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2609578298\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2609578298?lang=zh_TW&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-02-08 11:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609578298","market":"hk","top_or_hot":-1,"title":"Roivant Sciences (ROIV) Q3 Loss Of US$265.9 Million Tests Bullish Profitability Narrative","media":"Simply Wall St.","content":"<div>\n<p>Roivant Sciences (ROIV) just posted its Q3 2026 numbers with total revenue of about US$2.0 million and a basic EPS loss of US$0.38, alongside a net income loss, excluding extra items, of US$265.9 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/roivant-sciences-roiv-q3-loss-of-us2659-million-tests-bullis\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roivant Sciences (ROIV) Q3 Loss Of US$265.9 Million Tests Bullish Profitability Narrative</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoivant Sciences (ROIV) Q3 Loss Of US$265.9 Million Tests Bullish Profitability Narrative\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Simply Wall St.</strong><span class=\"h-time small\">2026-02-08 11:11</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>Roivant Sciences (ROIV) just posted its Q3 2026 numbers with total revenue of about US$2.0 million and a basic EPS loss of US$0.38, alongside a net income loss, excluding extra items, of US$265.9 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/roivant-sciences-roiv-q3-loss-of-us2659-million-tests-bullis\">网页链接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/roivant-sciences-roiv-q3-loss-of-us2659-million-tests-bullis\">Simply Wall St.</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4112","symbol_name":"金融交易所和數據","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/roivant-sciences-roiv-q3-loss-of-us2659-million-tests-bullis","article_id":"2609578298","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/roivant-sciences-roiv-q3-loss-of-us2659-million-tests-bullis","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2609578298","pubTimestamp":1770520284,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Roivant Sciences (ROIV) just posted its Q3 2026 numbers with total revenue of about US$2.0 million and a basic EPS loss of US$0.38, alongside a net income loss, excluding extra items, of US$265.9 million. The company has seen quarterly revenue move from US$9.0 million in Q3 2025 to US$2.0 million in Q3 2026, while basic EPS shifted from a loss of US$0.22 to a loss of US$0.38 over the same period. This sets the scene for investors to weigh near term revenue scale against the size of ongoing...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4112":"金融交易所和数据","ROIV":"Roivant Sciences Ltd.","BK4139":"生物科技","BK4007":"制药"},"translate_title":"Roivant Sciences(ROIV)第三季度亏损2.659亿美元考验看涨的盈利能力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ROIV":1.98},"content_text":"Roivant Sciences (ROIV) just posted its Q3 2026 numbers with total revenue of about US$2.0 million and a basic EPS loss of US$0.38, alongside a net income loss, excluding extra items, of US$265.9 million. The company has seen quarterly revenue move from US$9.0 million in Q3 2025 to US$2.0 million in Q3 2026, while basic EPS shifted from a loss of US$0.22 to a loss of US$0.38 over the same period. This sets the scene for investors to weigh near term revenue scale against the size of ongoing losses and consider what that implies for margins going forward. See our full analysis for Roivant Sciences. With the headline numbers on the table, the next step is to see how this latest earnings snapshot lines up with the widely followed growth and profitability narratives around Roivant. Curious how numbers become stories that shape markets? Explore Community Narratives NasdaqGS:ROIV Earnings & Revenue History as at Feb 2026 AdvertisementLosses Stay Large With US$809.2 Million TTM Net Loss  On a trailing 12 month basis, Roivant booked a net income loss, excluding extra items, of US$809.2 million on US$13.3 million of total revenue, which keeps the business firmly in loss making territory despite the earlier comment that losses have been reduced over the past five years. What stands out against the generally bullish view that earnings could grow about 50.97% per year is that recent quarterly losses remain heavy, with Q3 2026 alone showing a US$265.9 million net loss and basic EPS loss of US$0.38. This leaves a wide gap between current results and that optimistic path.\n     Bulls often focus on that 28.2% annual reduction in losses over five years, but the latest trailing 12 month loss is still over US$800 million, so the reported trend has not yet translated into small or marginal losses. The idea that Roivant might become profitable within three years is therefore being measured against a starting point where revenue for Q3 2026 was just under US$2.0 million. Any improvement would need to be assessed alongside these relatively small current revenue levels.    Investors who are tracking that long run earnings story may want a clearer bridge between the current US$809.2 million annual loss and the expected improvement, and 📊 Read the full Roivant Sciences Consensus Narrative. can help frame how others are thinking about that gap. Revenue Base Shrinks While Pipeline Count Holds Steady  Quarterly revenue has moved from US$9.0 million in Q3 2025 to US$1.999 million in Q3 2026, while through 2026 the company has reported 8 products in Phase II and 3 in Phase III in both Q1 and Q2. The development portfolio count therefore stayed unchanged in those periods even as revenue stayed in the low single digit millions. Supporters who focus on Roivant as a multi asset pipeline story may point to those 8 Phase II and 3 Phase III programs as the main drivers behind the strong revenue and earnings growth forecasts, yet the current numbers underline that these assets have not yet translated into large recurring revenue.\n     Q1 2026 revenue of US$2.17 million and Q2 2026 revenue of US$1.571 million sit in the same small range as Q3 2026, which keeps the business in a pre scale phase even with multiple late stage projects reported. The contrast between a forecast 63.8% revenue growth rate and the present sub US$3 million quarterly revenue level means any future change in commercialisation or partnering would have an outsized impact on how those forecasts are interpreted.    Mixed Valuation Signals With P/B At 4.3x  Roivant is reported to be trading on a P/B of 4.3x, which is higher than the US Biotechs industry average of 2.5x but below the 9.2x peer average, so the shares sit between broader sector and closer peer benchmarks while the current share price is US$25.82. Critics who question the bullish stance highlight that the shares carry that above industry P/B multiple even though the trailing 12 month net loss is US$809.2 million and trailing 12 month revenue is US$13.3 million, so valuation is being supported more by the growth outlook than by present profitability.\n     The fact that earnings are still negative on both the latest quarter and trailing 12 month view, while analysts still expect profitability within three years, shows how much weight the market places on those forecasts rather than current margins. At the same time, the P/B being below the 9.2x peer average suggests some investors may view the stock as less aggressively valued than certain direct comparables, even though it remains unprofitable on the latest reported figures.     Next Steps Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Roivant Sciences's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move. See What Else Is Out There Roivant is still carrying heavy losses on a small revenue base, with profitability forecasts leaning on future expectations rather than current financial strength. If that mix of large losses and limited revenue scale feels uncomfortable, shift your focus toward companies with steadier fundamentals by checking out 83 resilient stocks with low risk scores today.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}